Sanofi cuts the cord on collaboration deal with KaloBios

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi Pasteur (SNY +0.5%) (OTCQB:SNYNF) terminates its collaboration and licensing agreement with KaloBios Pharmaceuticals (KBIO -1%) for KB001-A. Sanofi had been developing the monoclonal antibody as a treatment for Pseudomonas aeruginosa ((Pa)) pneumonia prevention while KaloBios was developing it as a treatment for chronic Pa lung infections in cystic fibrosis patients.

Sanofi agreed to terminate in consideration of low single-digit royalties on KB001-A net sales, subject to a $40M cap.